Switch to Unboosted Atazanavir With Tenofovir (SUAT) Study

Trial Profile

Switch to Unboosted Atazanavir With Tenofovir (SUAT) Study

Completed
Phase of Trial: Phase IV

Latest Information Update: 09 Jan 2017

At a glance

  • Drugs Atazanavir (Primary) ; Atazanavir/ritonavir
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms SUAT
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 09 Jan 2017 Primary endpoint (Proportion of subjects without treatment failure at 48 weeks) has not been met, according to results published in the HIV Clinical Trials Journal.
    • 09 Jan 2017 Results published in the HIV Clinical Trials Journal.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top